肾脏病随机临床试验中女性领导与参与的系统综述
该文献计量综述筛查了2011至2021年顶级期刊的1770项研究,纳入395项肾脏病随机对照试验,分析女性作为通讯作者等领导角色及女性受试者参与情况。结果显示女性领导比例低且无改善,女性受试者中位占比39.0%,男性主导试验入组女性更少,女性领导获产业资助和国际试验的可能性更低。
要点
- 女性通讯作者、第一作者和最后作者占比分别为22%、28%和19%,随时间无变化。
- 女性受试者中位占比39.0%,女性与男性领导的试验无差异。
- 女性领导获产业资助和国际试验的OR分别为0.30和0.11。
核心结论
- 肾脏病随机对照试验中女性领导与参与存在性别不平等,且未随时间改善。
主要发现
- 女性通讯作者、第一作者和最后作者占比分别为22%、28%和19%,无时间变化(P=0.94)。
- 女性受试者中位百分比为39.0%(四分位距13.5%),女性与男性领导的试验无差异(P=0.15)。
- 男性领导的试验入组女性受试者统计学上更少。
- 女性领导获产业资助的OR为0.30(95%CI 0.14-0.63,P=0.002),领导国际试验的OR为0.11(95%CI 0.01-0.83,P=0.03)。
- 有性别特异性入选标准的试验更可能有女性领导(OR 2.56,95%CI 1.19-5.49,P=0.02)。
临床怎么用
- 肾脏病临床试验设计时应关注女性受试者入组和女性领导代表性,并评估改善不平等的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Women are underrepresented in the leadership of and participation in randomized controlled trials (RCTs). We conducted a bibliometric review of nephrology RCTs to examine trial leadership by women and participation of women in nephrology RCTs. METHODS: A bibliometric review of RCTs published in top medical, surgical, or nephrology journals was conducted using MEDLINE and EMBASE from January 2011 to December 2021. Leadership by women as corresponding authors, women trial participation, and trial characteristics were examined with duplicate independent data extraction. Logistic regression was used to examine associations between trial characteristics and women leadership and trial participation. RESULTS: A total of 1770 studies were screened and 395 RCTs met eligibility criteria. The number (%) of women in corresponding, first, and last authorship positions were as follows: 89 (22%), 109 (28%), and 74 (19%), respectively, without change over time (P = 0.94). The median percentage (interquartile range [IQR]) of women trial participants was 39.0% (13.5%) with no difference between women or men lead authors (P = 0.15). Men lead authors were statistically less likely to enroll women in RCTs. Women lead authors were less likely to be funded by industry (odds ratio [OR]: 0.30; 95% confidence interval [CI]: 0.14-0.63; P = 0.002) or lead international trials (OR: 0.11; 95% CI: 0.01-0.83; P = 0.03). Trials with sex-specific eligibility criteria were more likely to have women leaders (OR: 2.56; 95% CI: 1.19-5.49; P = 0.02) than those without. DISCUSSION: Gender inequalities in RCT leadership and RCT participation exist in nephrology and did not improve over time. Strategies to improve inequalities need to be implemented and evaluated.
引用
- Lodhi S, Kibret T, Mangalgi S, et al. Systematic Review of Women Leading and Participating in Nephrology Randomized Clinical Trials. Kidney Int Rep. 2024. PMID: 38765601. doi:10.1016/j.ekir.2024.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。